Abstract
The increasing cancer-related mortality related to rapid decreases in blood pressure from the pharmacologic treatment of hypertension as seen in the Systolic Hypertension in the Elderly Program (SHEP; [1][1]) draws interesting parallels to the PROspective Study of Pravastatin in the Elderly at Risk
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
